Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Consolidated Net Income: 2013-2025

Historic Consolidated Net Income for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $9.0 million.

  • Coherus Oncology's Consolidated Net Income fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • As of Q3 2025, Coherus Oncology's Consolidated Net Income stood at $9.0 million, which was down 97.38% from $342.6 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Consolidated Net Income peaked at $342.6 million during Q2 2025, and registered a low of -$172.9 million during Q1 2021.
  • Moreover, its 3-year median value for Consolidated Net Income was $9.0 million (2025), whereas its average is $50.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 586.19% in 2021, then skyrocketed by 717.15% in 2025.
  • Over the past 5 years, Coherus Oncology's Consolidated Net Income (Quarterly) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.30% to -$79.7 million in 2023, then surged by 348.34% to $197.8 million in 2024, then crashed by 75.61% to $9.0 million in 2025.
  • Its Consolidated Net Income was $9.0 million in Q3 2025, compared to $342.6 million in Q2 2025 and -$9.2 million in Q1 2025.